Drug Profile

Colestyramine - Albireo

Alternative Names: A 3384

Latest Information Update: 06 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Albireo AB
Developer Albireo AB; Albireo Pharma
Class Antidiarrhoeals; Antihyperlipidaemics
Mechanism of Action Bile acid binding protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase II Primary bile acid malabsorption
No development reported Intrahepatic cholestasis

Most Recent Events

02 Mar 2023 Albireo Pharma has been acquired by Ipsen
10 May 2019 ALBIREO PHARMA plans a clinical trial for Primary bile acid malabsorption in USA in 2020
23 Nov 2016 No recent reports on development identified - Phase-I for Intrahepatic cholestasis (Combination therapy, In volunteers) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com